BioWorld

Oct. 15, 2003

View Archived Issues

Built To Last' Reata Taking Aim At Cancer, Neurological Diseases

Read More

Immune Response Adds Cash, Raises $12M For HIV Vaccines

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More

CoTherix Acquires Schering's U.S. Rights For Ventavis, Raises $55M

The company formerly known as Exhale Therapeutics Inc. has acquired a new name, a new financing and new U.S. rights to a pulmonary hypertension product. (BioWorld Today) Read More

Dyax To Receive $35M Through Biotage Sale To Pyrosequencing

Read More